Table 4.
Loras 2009 (study 1) | Chevaux 2010 (study 2) | Our IBD study | Study 1 vs our study (P value) | Study 2 vs our study (P value) | |
Chronic HBV (HBsAg) | 0.7% | 0.95% | 1.8% | 0.070 | 0.159 |
Exposure to HBV (Anti-HBc Ab) | 7.5% | 2.50% | 3.2% | 0.006 | 0.313 |
IBD: Inflammatory bowel disease; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; anti-HBc Ab: Hepatitis B core antibodies.